EUVIMEDOpdag EUVIMED
Crossref

Evaluation of suppressor behavior of guanidine‐derived metformin and galegine as novel potential drugs for cancer treatment: an in silico study

Mohammad Behrouzi Varjovi iD, Rasool Asghari-Zakaria, Ghader Hosseinzadeh

Biotechnology and Applied Biochemistry · 2024

DOI: 10.1002/bab.2636 ↗

At a glance

Journal article in Biotechnology and Applied Biochemistry, 2024. Written by Mohammad Behrouzi Varjovi and 2 co-authors. Institution: Faculty of Agriculture, Department of Crop Production and Genetics, University of Mohaghegh Ardabili, Ardabil, Iran. Major MEDLINE topics: Metformin, Neoplasms. Cited 1 times so far (Crossref); 44 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

There are some natural products from plants that can prevent and treat disease. Metformin, a derivative of galegine, is the basic drug to treat diabetes. Moreover, this molecule has anticancer properties that inhibit cancer cell growth and proliferation. In this study, the main interactions of galegine and metformin with various cancer‐involved proteins, including mitochondrial alpha‐glycerophosphate dehydrogenase, yeast NADH dehydrogenase, and transforming growth factor‐β1, were surveyed by molecular docking and molecular dynamics simulations. The results showed that each of the proteins makes complexes with the ligands via favorable non‐bonded interactions, especially hydrogen bond interactions. There is greater stability for complexes containing galegine based on the root mean square deviation results. The higher structure compactness is also found in galegine receptors than in metformin receptors. Calculation of Δ G binding , using the MM/PBSA methodology, shows that the binding energy values for metformin and galegine in interaction with each of the receptors are almost the same, and galegine has similar binding properties with metformin in interaction with the studied protein receptors. Therefore, galegine, a natural ingredient with better binding properties to cancer‐involved proteins than metformin (with various side effects), can be applied as a new drug for cancer treatment.

Subjects

MeSH terms (MEDLINE)

MetforminNeoplasmsHumansAntineoplastic AgentsMolecular Docking SimulationGuanidineMolecular Dynamics SimulationGlycerolphosphate DehydrogenaseComputer Simulation

Author keywords

Ndi1TGF‐β1galeginemGPDmetforminmolecular dynamics simulation

Substances

MetforminAntineoplastic AgentsGuanidineGlycerolphosphate Dehydrogenase

Authors and institutions

  • Faculty of Agriculture, Department of Crop Production and Genetics, University of Mohaghegh Ardabili, Ardabil, Iran.
  • Faculty of Engineering, Department of Chemical Engineering, University of Bonab, Bonab, Iran.

ORCID profiles: Mohammad Behrouzi Varjovi

Cite

APA

Behrouzi Varjovi, M., Asghari-Zakaria, R., & Hosseinzadeh, G. (2024). Evaluation of suppressor behavior of guanidine‐derived metformin and galegine as novel potential drugs for cancer treatment: an in silico study. Biotechnology and Applied Biochemistry. https://doi.org/10.1002/bab.2636

Vancouver

Behrouzi Varjovi M, Asghari-Zakaria R, Hosseinzadeh G. Evaluation of suppressor behavior of guanidine‐derived metformin and galegine as novel potential drugs for cancer treatment: an in silico study. Biotechnology and Applied Biochemistry. 2024. doi:10.1002/bab.2636

BibTeX
@article{BehrouziVarjovi2024,
  author = {Behrouzi Varjovi, Mohammad and Asghari-Zakaria, Rasool and Hosseinzadeh, Ghader},
  title = {Evaluation of suppressor behavior of guanidine‐derived metformin and galegine as novel potential drugs for cancer treatment: an in silico study},
  journal = {Biotechnology and Applied Biochemistry},
  year = {2024},
  doi = {10.1002/bab.2636}
}
Start for free →